Table 2

Functional and structural outcomes after switch to brolucizumab

OutcomeMean±SD95% CIP value
Change BCVA (logMAR)0.03±0.14(−0.01 to 0.06)0.115
Change FCP (µm)−66.81±72.63(−85.10 to −48.52)<0.001
Change CSRT (µm)−66.76±60.71(−82.05 to −51.47)<0.001
Change macular volume (mm³)−0.27±0.24(−0.33 to −0.20)<0.001
  • BCVA, best-corrected visual acuity; CSRT, central subfield retinal thickness; FCP, foveal centre point.